SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS)SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS)SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS)

SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS)

No trades
See on Supercharts
Market capitalization
‪84.66 M‬CHF
‪−71.08 M‬CHF
‪7.47 M‬CHF
‪6.63 M‬
Beta (1Y)
−1.02

About SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS)

CEO
Dario Eklund
Headquarters
Pratteln
Employees (FY)
51
Founded
1998
ISIN
CH1276028821
FIGI
BBG00JYV5H90
Santhera Pharmaceuticals Holding AG engages in the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases. Its product pipeline includes Vamorolone and Lonodelestat. The company was founded by Thomas Meier in 1998 and is headquartered in Pratteln, Switzerland.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of 0QN1 is 9.53 CHF — it has increased by 1.90% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) stocks are traded under the ticker 0QN1.
SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) is going to release the next earnings report on Apr 25, 2024. Keep track of upcoming events with our Earnings Calendar.
0QN1 stock is 1.88% volatile and has beta coefficient of −1.02. Check out the list of the most volatile stocks — is SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) there?
Yes, you can track SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) financials in yearly and quarterly reports right on TradingView.
0QN1 stock has fallen by 1.24% compared to the previous week, the month change is a 1.77% fall, over the last year SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) has showed a 47.48% increase.
Today SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) has the market capitalization of ‪100.56 M‬, it has increased by 4.84% over the last week.
No, 0QN1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 0QN1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) stock right from TradingView charts — choose your broker and connect to your account.
0QN1 reached its all-time high on Feb 19, 2018 with the price of 292.50 CHF, and its all-time low was 5.30 CHF and was reached on Dec 7, 2022.
See other stocks reaching their highest and lowest prices.
As of Apr 25, 2024, the company has 51.00 employees. See our rating of the largest employees — is SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) stock shows the neutral signal. See more of SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) future price: according to them, 0QN1 price has a max estimate of 30.00 CHF and a min estimate of 13.00 CHF. Read a more detailed SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) forecast: see what analysts think of SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) and suggest that you do with its stocks.